Moving Fast Toward Hepatitis B Virus Elimination.

[1]  Y. Nie,et al.  Combination drug interactions of hepatitis B virus (HBV) S-antigen transport - inhibiting oligonucleotide polymers in vitro , 2020, Journal of Hepatology.

[2]  M. Yuen,et al.  RO7062931 antisense oligonucleotide phase 1 study demonstrates target engagement in patients with chronic hepatitis B on established nucleos(t)ide therapy , 2020, Journal of Hepatology.

[3]  W. Talloen,et al.  Virology analysis of chronic hepatitis B virus–infected patients treated for 28 days with JNJ‐56136379 monotherapy , 2020, Journal of viral hepatitis.

[4]  H. Razavi.  Global Epidemiology of Viral Hepatitis. , 2020, Gastroenterology clinics of North America.

[5]  P. Zhao,et al.  Anti–PD-1/PD-L1 Blockade Immunotherapy Employed in Treating Hepatitis B Virus Infection–Related Advanced Hepatocellular Carcinoma: A Literature Review , 2020, Frontiers in Immunology.

[6]  Helen Yu,et al.  Discovery of GS-9688 (Selgantolimod), as a Potent and Selective Oral Toll-like Receptor 8 Agonist for the Treatment of Chronic Hepatitis B. , 2020, Journal of medicinal chemistry.

[7]  T. Racek,et al.  A Single and Multiple Ascending Dose Study of Toll‐Like Receptor 7 Agonist (RO7020531) in Chinese Healthy Volunteers , 2020, Clinical and translational science.

[8]  R. Mackman,et al.  Toll‐Like Receptor 8 Agonist GS‐9688 Induces Sustained Efficacy in the Woodchuck Model of Chronic Hepatitis B , 2020, Hepatology.

[9]  E. Gallicchio,et al.  Amide-containing α-hydroxytropolones as inhibitors of hepatitis B virus replication. , 2020, Antiviral research.

[10]  R. Colonno,et al.  Rapid Turnover of Hepatitis B Virus Covalently Closed Circular DNA Indicated by Monitoring Emergence and Reversion of Signature‐Mutation in Treated Chronic Hepatitis B Patients , 2020, Hepatology.

[11]  Ding‐Shinn Chen,et al.  Permanent Inactivation of HBV Genomes by CRISPR/Cas9-Mediated Non-cleavage Base Editing , 2020, Molecular therapy. Nucleic acids.

[12]  F. Carrilho,et al.  Adverse events of nucleos(t)ide analogues for chronic hepatitis B: a systematic review , 2020, Journal of Gastroenterology.

[13]  I. Kassab,et al.  Agonist and antagonist ligands of toll-like receptors 7 and 8: Ingenious tools for therapeutic purposes , 2020, European Journal of Medicinal Chemistry.

[14]  M. Bazinet,et al.  Safety and Efficacy of 48 Weeks REP 2139 or REP 2165, Tenofovir Disoproxil, and Pegylated Interferon Alfa-2a in Patients With Chronic HBV Infection Naïve to Nucleos(t)ide Therapy. , 2020, Gastroenterology.

[15]  F. Zoulim,et al.  Can we cure hepatitis B virus with novel direct‐acting antivirals? , 2020, Liver international : official journal of the International Association for the Study of the Liver.

[16]  F. Zoulim,et al.  Author Correction: Therapeutic strategies for hepatitis B virus infection: towards a cure , 2020, Nature Reviews Drug Discovery.

[17]  J. Feld,et al.  Review article: clinical pharmacology of current and investigational hepatitis B virus therapies , 2019, Alimentary pharmacology & therapeutics.

[18]  Qiang Liu,et al.  A dendritic cell-targeted chimeric hepatitis B virus immunotherapeutic vaccine induces both cellular and humoral immune responses in vivo , 2019, Human vaccines & immunotherapeutics.

[19]  M. Buti,et al.  Guidance for Design and Endpoints of Clinical Trials in Chronic Hepatitis B—Report From the 2019 EASL‐AASLD HBV Treatment Endpoints Conference , 2019, Hepatology.

[20]  R. Schinazi,et al.  Novel Hepatitis B Virus Capsid Assembly Modulator Induces Potent Antiviral Responses In Vitro and in Humanized Mice , 2019, Antimicrobial Agents and Chemotherapy.

[21]  F. Zoulim,et al.  Guidance for design and endpoints of clinical trials in chronic hepatitis B - Report from the 2019 EASL-AASLD HBV Treatment Endpoints Conference. , 2019, Journal of hepatology.

[22]  M. Yuen,et al.  Safety, pharmacokinetics, and antiviral effects of ABI-H0731, a hepatitis B virus core inhibitor: a randomised, placebo-controlled phase 1 trial. , 2019, The lancet. Gastroenterology & hepatology.

[23]  R. Schinazi,et al.  Long-term Virological and Adherence Outcomes to Antiviral Treatment in a 4-year Cohort Chronic HBV Study , 2019, Antiviral Therapy.

[24]  Xia Zhao,et al.  A First-in-Human Trial of GLS4, a Novel Inhibitor of Hepatitis B Virus Capsid Assembly, following Single- and Multiple-Ascending-Oral-Dose Studies with or without Ritonavir in Healthy Adult Volunteers , 2019, Antimicrobial Agents and Chemotherapy.

[25]  F. Zoulim,et al.  Safety and immunogenicity of the therapeutic vaccine TG1050 in chronic hepatitis B patients: a phase 1b placebo-controlled trial , 2019, Human vaccines & immunotherapeutics.

[26]  F. Zoulim,et al.  Therapeutic strategies for hepatitis B virus infection: towards a cure , 2019, Nature Reviews Drug Discovery.

[27]  S. V. D. van de Graaf,et al.  Mechanistic insights into the inhibition of NTCP by myrcludex B , 2019, JHEP reports.

[28]  D. Ure,et al.  The cyclophilin inhibitor CRV431 inhibits liver HBV DNA and HBsAg in transgenic mice , 2019, PloS one.

[29]  G. Missale,et al.  HBV Immune-Therapy: From Molecular Mechanisms to Clinical Applications , 2019, International journal of molecular sciences.

[30]  Ryan L Setten,et al.  The current state and future directions of RNAi-based therapeutics , 2019, Nature Reviews Drug Discovery.

[31]  Sae-Hwan Lee,et al.  KASL clinical practice guidelines for management of chronic hepatitis B , 2019, Clinical and molecular hepatology.

[32]  Tao Xu,et al.  Potential resistant mutations within HBV reverse transcriptase sequences in nucleos(t)ide analogues-experienced patients with hepatitis B virus infection , 2019, Scientific Reports.

[33]  J. Tavis,et al.  Shedding light on RNaseH: a promising target for hepatitis B virus (HBV) , 2019, Expert opinion on therapeutic targets.

[34]  J. Tavis,et al.  Chemical Approaches to Inhibiting the Hepatitis B Virus Ribonuclease H. , 2019, ACS infectious diseases.

[35]  Choongho Lee.  CRISPR/Cas9-Based Antiviral Strategy: Current Status and the Potential Challenge , 2019, Molecules.

[36]  H. Bonkovsky,et al.  FRI-442-Acute hepatic porphyria disease manifestations and daily life impacts in EXPLORE international, prospective, natural history study , 2019, Journal of Hepatology.

[37]  W. Haefeli,et al.  GS-13-Final results of a multicenter, open-label phase 2 clinical trial (MYR203) to assess safety and efficacy of myrcludex B in cwith PEG-interferon Alpha 2a in patients with chronic HBV/HDV co-infection , 2019, Journal of Hepatology.

[38]  M. Yuen,et al.  FRI-219-RO7049389, a core protein allosteric modulator, demonstrates robust decline in HBV DNA and HBV RNA in chronic HBV infected patients , 2019, Journal of Hepatology.

[39]  S. Tasker,et al.  PS-078-A phase 1b evaluation of HepTcell HBV-specific immunotherapy in nuc-controlled, eAg negative chronic HBV infection , 2019, Journal of Hepatology.

[40]  B. Goodwin,et al.  FRI-191-EDP-514, a novel HBV core inhibitor with potent antiviral activity both in vitro and in vivo , 2019, Journal of Hepatology.

[41]  R. Schinazi,et al.  FRI-157-Novel HBV capsid assembly modulator inhibits pregenomic RNA encapsidation by accelerating capsid assembly kinetics and disrupting core protein dephosphorylation , 2019, Journal of Hepatology.

[42]  J. Tavis,et al.  Inhibition of HBV replication by N‐hydroxyisoquinolinedione and N‐hydroxypyridinedione ribonuclease H inhibitors , 2019, Antiviral research.

[43]  F. Thiele,et al.  FRI-209-Exploring TH1/TH2 adjuvants to improve the efficacy of the therapeutic vaccination against chronic hepatitis B , 2019, Journal of Hepatology.

[44]  M. Bures,et al.  PS-073-Preclinical profile of HBV core protein inhibitor, ABI-H, a potent inhibitor of cccDNA generation in HBV infected cells , 2019, Journal of Hepatology.

[45]  R. Elston,et al.  A Randomized, Double‐Blind, Placebo‐Controlled, First‐Time‐in‐Human Study to Assess the Safety, Tolerability, and Pharmacokinetics of Single and Multiple Ascending Doses of GSK3389404 in Healthy Subjects , 2019, Clinical pharmacology in drug development.

[46]  T. Yarovinsky,et al.  Virus-like Vesicles Expressing Multiple Antigens for Immunotherapy of Chronic Hepatitis B , 2018, bioRxiv.

[47]  Y. Ni,et al.  T5 Exonuclease Hydrolysis of Hepatitis B Virus Replicative Intermediates Allows Reliable Quantification and Fast Drug Efficacy Testing of Covalently Closed Circular DNA by PCR , 2018, Journal of Virology.

[48]  A. Vaillant.  REP 2139: Antiviral Mechanisms and Applications in Achieving Functional Control of HBV and HDV Infection. , 2018, ACS infectious diseases.

[49]  C. Schuster,et al.  The functional role of sodium taurocholate cotransporting polypeptide NTCP in the life cycle of hepatitis B, C and D viruses , 2018, Cellular and Molecular Life Sciences.

[50]  H. Yi,et al.  A novel SMAC mimetic APG‐1387 exhibits dual antitumor effect on HBV‐positive hepatocellular carcinoma with high expression of cIAP2 by inducing apoptosis and enhancing innate anti‐tumor immunity , 2018, Biochemical pharmacology.

[51]  M. Ghany,et al.  Disease Pathways and Mechanisms of Potential Drug Targets , 2018, Clinical liver disease.

[52]  Jinhong Chang,et al.  Virological Basis for the Cure of Chronic Hepatitis B. , 2018, ACS infectious diseases.

[53]  Zhenghong Yuan,et al.  In vitro studies identify a low replication phenotype for hepatitis B virus genotype H generally associated with occult HBV and less severe liver disease. , 2018, Virology.

[54]  R. Schinazi,et al.  Novel and potent HBV capsid modulator reduces HBeAg and cccDNA in core site directed T109I mutant in HepNTCP cells , 2018 .

[55]  Zhanhui Wang,et al.  Inhibition of hepatitis B virus replication via HBV DNA cleavage by Cas9 from Staphylococcus aureus , 2018, Antiviral research.

[56]  T. Asselah,et al.  Towards HBV curative therapies , 2018, Liver international : official journal of the International Association for the Study of the Liver.

[57]  A. Bertoletti,et al.  Immunotherapy for Chronic Hepatitis B Virus Infection , 2018, Gut and liver.

[58]  M. Mutchnick,et al.  Immunotherapy for hepatitis B in the direct acting antiviral era: Reevaluating the thymosin α1 efficacy trials in the light of a combination therapy approach , 2018, Journal of viral hepatitis.

[59]  D. Ure,et al.  In Vitro Phase I Metabolism of CRV431, a Novel Oral Drug Candidate for Chronic Hepatitis B , 2017, Pharmaceutics.

[60]  Joong-Yang Cho,et al.  Clevudine Induced Mitochondrial Myopathy , 2017, Journal of Korean medical science.

[61]  J. Tavis,et al.  Efficacy and cytotoxicity in cell culture of novel &agr;‐hydroxytropolone inhibitors of hepatitis B virus ribonuclease H , 2017, Antiviral research.

[62]  Thomas Berg,et al.  EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. , 2017, Journal of hepatology.

[63]  J. Tavis,et al.  Inhibition of hepatitis B virus replication by N‐hydroxyisoquinolinediones and related polyoxygenated heterocycles , 2017, Antiviral research.

[64]  Hung‐Chih Yang,et al.  The potential and challenges of CRISPR-Cas in eradication of hepatitis B virus covalently closed circular DNA. , 2017, Virus research.

[65]  B. McMahon,et al.  Use of Current and New Endpoints in the Evaluation of Experimental Hepatitis B Therapeutics , 2017, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[66]  R. Schinazi,et al.  Synthesis and antiviral evaluation of 2',2',3',3'-tetrafluoro nucleoside analogs. , 2017, Tetrahedron letters.

[67]  A. Vaillant.  Nucleic acid polymers : Broad spectrum antiviral activity , antiviral mechanisms and optimization for the treatment of hepatitis B and hepatitis D infection , 2016 .

[68]  M. Bazinet,et al.  Safety and Efficacy of Nucleic Acid Polymers in Monotherapy and Combined with Immunotherapy in Treatment-Naive Bangladeshi Patients with HBeAg+ Chronic Hepatitis B Infection , 2016, PloS one.

[69]  P. André,et al.  Reciprocal regulation of farnesoid X receptor α activity and hepatitis B virus replication in differentiated HepaRG cells and primary human hepatocytes , 2016, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[70]  M. Maini,et al.  The role of innate immunity in the immunopathology and treatment of HBV infection. , 2016, Journal of hepatology.

[71]  A. Olveira,et al.  Hepatitis B and D viruses replication interference: Influence of hepatitis B genotype. , 2016, World journal of gastroenterology.

[72]  V. Kim,et al.  Pegylated interferon alfa for chronic hepatitis B: systematic review and meta‐analysis , 2016, Journal of viral hepatitis.

[73]  Yong-Yuan Zhang,et al.  Rethinking the pathogenesis of hepatitis B virus (HBV) infection , 2015, Journal of medical virology.

[74]  B. Cullen,et al.  Targeting hepatitis B virus cccDNA using CRISPR/Cas9. , 2015, Antiviral research.

[75]  M. Nassal.  HBV cccDNA: viral persistence reservoir and key obstacle for a cure of chronic hepatitis B , 2015, Gut.

[76]  Chunsheng Dong,et al.  Targeting hepatitis B virus cccDNA by CRISPR/Cas9 nuclease efficiently inhibits viral replication. , 2015, Antiviral research.

[77]  C. Begley,et al.  Eliminating hepatitis B by antagonizing cellular inhibitors of apoptosis , 2015, Proceedings of the National Academy of Sciences.

[78]  Myeong Jun Song,et al.  Safety and immunogenicity of therapeutic DNA vaccine with antiviral drug in chronic HBV patients and its immunogenicity in mice , 2015, Liver international : official journal of the International Association for the Study of the Liver.

[79]  Y. Poovorawan,et al.  A rational study for identification of highly effective siRNAs against hepatitis B virus. , 2014, Experimental and molecular pathology.

[80]  Hong-wei Zhang,et al.  Virus-related liver cirrhosis: molecular basis and therapeutic options. , 2014, World journal of gastroenterology.

[81]  T. Liang,et al.  Specific and Nonhepatotoxic Degradation of Nuclear Hepatitis B Virus cccDNA , 2014, Science.

[82]  Juan Lu,et al.  Inhibition of Hepatitis B Virus cccDNA by siRNA in Transgenic Mice , 2014, Cell Biochemistry and Biophysics.

[83]  Wenhui Li,et al.  Sodium taurocholate cotransporting polypeptide is a functional receptor for human hepatitis B and D virus , 2012, eLife.

[84]  P. Marcellin,et al.  Influence of genotype on hepatitis B surface antigen kinetics in hepatitis B e antigen-negative patients treated with pegylated interferon-α2a , 2009, Antiviral therapy.

[85]  H. Tillmann.  The treatment of chronic hepatitis B: Focus on adefovir-like antivirals , 2008, Therapeutics and clinical risk management.

[86]  J. Koskinas,et al.  Intrahepatic levels and replicative activity of covalently closed circular hepatitis B virus DNA in chronically infected patients , 2006, Hepatology.

[87]  G. Gerken,et al.  Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial , 2005, The Lancet.

[88]  H. Giladi,et al.  Small interfering RNA inhibits hepatitis B virus replication in mice. , 2003, Molecular therapy : the journal of the American Society of Gene Therapy.

[89]  C. Katlama,et al.  In Vitro Susceptibility of Lamivudine-Resistant Hepatitis B Virus to Adefovir and Tenofovir , 2003, Antiviral therapy.

[90]  R. Schinazi,et al.  The polymerase L528M mutation cooperates with nucleotide binding-site mutations, increasing hepatitis B virus replication and drug resistance. , 2001, The Journal of clinical investigation.

[91]  A. Caudy,et al.  Role for a bidentate ribonuclease in the initiation step of RNA interference , 2001 .

[92]  M. Yuen,et al.  Preliminary safety and antiviral activity of VIR-2218, an X-targeting HBV RNAi therapeutic, in chronic hepatitis B patients , 2020, Journal of Hepatology.

[93]  M. Biermer,et al.  Short-term treatment with RNA interference therapy, JNJ-3989, results in sustained hepatitis B surface antigen supression in patients with chronic hepatitis B receiving nucleos(t)ide analogue treatment , 2020, Journal of Hepatology.

[94]  J. Sagartz,et al.  Efficacy of hepatitis B virus ribonuclease H inhibitors, a new class of replication antagonists, in FRG human liver chimeric mice , 2018, Antiviral research.

[95]  J. Tavis,et al.  In Vitro Enzymatic and Cell Culture-Based Assays for Measuring Activity of HBV RNaseH Inhibitors. , 2017, Methods in molecular biology.